Nanostructured drug carriers for treatment and management of neuroendocrine cancer

In this era, nanocarriers used in drug delivery on top priority to treat cancer. Neuroendocrine (NE) cancer is a tumor that develops from neuroendocrine cells, which release hormones into the bloodstream and regulate body function. NE cancer can alter the normal function of neuroendocrine cells. Con...

Full description

Saved in:
Bibliographic Details
Main Authors: Kamdem, Marie Reine Maboune, Balmukund, Singh Vaibhav, Sudhakar, Kalvatala
Format: Conference Proceeding
Language:English
Subjects:
Anticancer properties
Cancer
Cancer therapies
Carbon nanotubes
Controllability
Dendrimers
Drug carriers
Hormones
Lipids
Nanomaterials
Nanoparticles
Prolongation
Quantum dots
Side effects
Therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this era, nanocarriers used in drug delivery on top priority to treat cancer. Neuroendocrine (NE) cancer is a tumor that develops from neuroendocrine cells, which release hormones into the bloodstream and regulate body function. NE cancer can alter the normal function of neuroendocrine cells. Conventional therapies have limitations for treating NE cancer cells which arise the need for specific nanocarriers that can target and enable the release of the drug in a sustainably and controllable manner. Nanocarriers like dendrimers, carbon nanotubes, liposomes, gold nanoparticles, solid lipid nanoparticles, quantum dots, polymer nanoparticles, magnetic nanoparticles, hybrid nanoparticles have the ability of spatial and temporal delivery. Nanomaterial used in nanocarriers plays an important role in the release rate of the drug, specific targeting, diagnostic purpose, and prolongation time. Nanocarriers have been used as a theranostic application in cancer therapy. Besides, the specific targeting potential of nanocarriers leads to diminished side effects. Additionally, surface-modified nanomaterials may offer better antitumor effects in NE cancer therapy. Hence, nanocarriers can be effectively employed for the management of NE cancer with specific targeting and minimal side effects relative to conventional therapy
ISSN:0094-243X
1551-7616
DOI:10.1063/5.0164750